Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Presentation made by Aagami at Lifesciences Summit at CGI - 18 May

3,326 views

Published on

The Consulate General India - Chicago organized a Life Science Summit on May 18, 2015 at Chicago

Mr. Dinesh Jain, Founder CEO, Aagami Inc. and Mr. Michael Rosen, Managing Director, Rosen Bioscience Strategies (also partner consultant at Aagami) attended the event as speakers and made a presentation on “Life Science Connections between the Midwest and India” as well as some of the life science M&A and FDI activity going on between the U.S. and India”

Published in: Government & Nonprofit
  • Be the first to comment

Presentation made by Aagami at Lifesciences Summit at CGI - 18 May

  1. 1. Realizing Possibilities, Together Aagami , Inc. | 2135 City Gate Lane, Suite 300, Naperville, IL 60653 USA | P: +1-630-364-1837 | www.aagami.com CROSS-BORDER LIFESCIENCES DEALS (2013-2015): A Perspective © Aagami, Inc. 2015 | All rights reserved | www.aagami.com Dinesh Jain| Michael Rosen
  2. 2. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 2 Table of Contents Overall Pharma Market Trends M&A Joint Ventures/Co-Development Licensing Aagami Profile CROSS BORDER LIFESCIENCES DEALS - US & INDIA (2013-2015) Note : These are some of the deals which Aagami Market Research Team have sourced from Publicly available data and hence not exhaustive
  3. 3. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 3 • Indian Pharma Market = ~ $22 B; projected to grow to $55 B by 2020 (McKinsey) • India pharma exports $15.2 B in pharmaceutical products ($4.2B to US) • 584 FDA –approved pharma manufacturing facilities • >3,000 pharma companies • Bi-national M&A (2013-2015)*  U.S. pharma spent more than $2.7 B to acquire Indian pharma  Indian pharma spent $180 M to acquire U.S. biotech and >$180 M in FDI * Counting only deal amounts which were publicly disclosed
  4. 4. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 4 Indian Co. US Co. Deal Size - M Year Remarks Aurobindo Natrol Inc. $132.5 2014 Nutraceuticals platform for US & ROW Piramal Coldstream Laboratories $30.65 2015 Injectable market segment SRF Dupont $ 20 .0 2015 Pharma propellant business Sun Pharma Pharmalucence N/A 2014 Radio- pharmaceuticals and US injectable business Kemwell Cirrus N/A 2013 Products with faster time-to-clinic and cost savings for customers
  5. 5. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 5 US Co. Indian Co. Deal Size - M Year Remarks Mylan Agila $1,600 2013 Become top-three global player in injectables Mylan Famy Care $800 2015 Global women's health care Hospira Orchid Pharma $200 2014 API supplier for key antibiotics and future API development. Carlyle Group Bharat Serum $83 2014 25-30% stake from existing investors. Amneal Pharma Epsilon Pharma $16 2014 Expand footprint in India. Includes 200,000 + sf. US FDA certified manufacturing facility. Quantum solutions Parexel N/A 2015 Create greater scale in service area, and provide comprehensive and efficient solution to global clients.
  6. 6. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 6 Indian Co. US Co. Year Remarks Ami Organics Photolitec 2015 Clinical trials to determine cancer treatments safety and and efficacy. Emami Hevert- Arzneimittel 2014 Launched products via 400 homoeopathy medicine retail outlets across diverse distribution channels via Emami. Agila Biotech Pfenex Inc 2013 Develop, manufacture and commercialize initial pipeline of 6 biosimilar products. AB = 51% equity stakeholder
  7. 7. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 7 Indian Co. US Co. Year Remarks Ipca Labs Oncobiologics 2014 Development, manufacture and commercialization of biosimilar monoclonal antibodies. Cipla BioQuiddity 2014 Commercial collaboration on OneDose ReadyfusOR™ in anaesthetic applications for post-surgical pain management. GVK Bio Endo Pharma 2013 Novel small molecules. GVK BIO will use discovery expertise and Endo will develop/commercialize product. Advinus Moffitt Cancer Centre 2013 New oncology therapies. GVK Bio Onconova Therapeutics 2013 US JV to move Onconova oncology assets from early discovery to clinical development stage. Cadila Novavax 2013 Extension to JV in 2009 collaboration to develop novel malaria vaccine in India.
  8. 8. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 8 Indian Co. US Co. Deal Size - M Year Remarks Lupin US Market $177.5 2014 2 new US R&D Centres on inhalation and complex formulations research. Glenmark US Market $100 2014 Greenfield facility for US market. Cipla Chase Pharma $6.0 2014 Alzheimer’s drug development. Part of $21 M investment through syndicate. Strides Arcolabs Oncobiologics N/A 2014 Strategic stake. Indian Co. US Co. Deal Size - M Year Remarks Laurus Lab Warburg Pincus $92 2014 Create durable businesses of scale with sustainable value. Ashland Investment in India $ 10 2014 2 centres of excellence — new pharma in Hyderabad and existing personal care in Mumbai
  9. 9. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 9 Indian Co. US Co. Year Remarks Sun Pharma Merck 2014 Worldwide rights to tildrakizumab. $ 280 M Deal MedGenome Natera 2015 Exclusive license to develop Natera's Panorama. Strides Arcolabs Gilead 2015 Non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF); license extends to 112 countries Natco India Gilead 2015 Generic versions of chronic hepatitis C medicines. Ranbaxy Epirus 2014 Infliximab (arthritis) with annual sales of $6 billion.. Biocon Cytosorbents Corporation 2014 Distribute CytoSorb® for critical care applications in ICU and cardiac surgery applications for India and select emerging countries. Indian Co. US Co. Year Remarks Caplin Point Fresenius Kabi 2015 Parenteral products; Fresenius Kabi will hold ANDAs and commercialise in USA.
  10. 10. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 10 Aagami, Inc. Life Sciences consulting firm based in Chicago suburbs offers: For Global Biotech, Pharmaceutical , Medical Devices and Consumer Health products companies. Strategic Consulting Services Technology Licensing Services Business & Market Research Services
  11. 11. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 11 Strategic Consulting Services  In-Licensing/Out-Licensing  Co-Development & Partnerships  Investments to/from US, India, Asia, Latin America  Mergers & Acquisitions  Finding the Right Partners  JV and/or Distributors  CRO/CRAMS providers  Contract Sales/Marketing  Contract Manufacturing
  12. 12. 12 Aagami Clients International Phosphagenics Australia PeptiSyntha Belgium DelMar Pharma Canada Affitech Denmark Pieris Germany Merus Holland Venus Remedies India Opsona Ireland Toppan Japan Otago University New Zealand Aagami has completed over 100 assignments for more than 50 clients in the last 11+ years. United States Advangene IL Loyola Univ. Chicago IL Dow Chemicals MI ScyFIX MN OncBioMune LA Penwest Corp. NY DesignMedix OR PLx TX CreAgri CA New Heaven Pharma CT
  13. 13. 13 Aagami Connectivity in India We are connected at CXO Level of TOP 100 Lifesciences companies in India including: Biocon Intas Sun Pharma Cadila Lupin Themis Cipla MicroLabs Torrent Pharma Dr Reddys Piramal USV Glenmark Reliance Wockhardt Hetero Drugs Strides Zydus
  14. 14. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com USA (Head Office) Aagami, Inc. 2135 City Gate Lane Suite 300 Naperville, IL 60653 P: +1-630-364-1837 INDIA Aagami 741, Nelson Square Nagpur – 440013 P: +91-712-258-6678 Dinesh Jain Email: dinesh@aagami.com M: +1 630-853-3520 Godwyn Francis Email: godwyn@aagami.com M: +91-787-501-6957 www.aagami.com 14 Realizing Possibilities, Together

×